[{"protocolSection": {"identificationModule": {"nctId": "NCT03834493", "briefTitle": "Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)", "officialTitle": "A Phase 3, Randomized, Double-blind Trial of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (KEYNOTE-641)"}, "descriptionModule": {"briefSummary": "The purpose of this study is to assess the efficacy and safety of the combination of pembrolizumab (MK-3475) and enzalutamide in the treatment of men with metastatic castration-resistant prostate cancer (mCRPC) who have not received chemotherapy for mCRPC, are abiraterone-na\u00efve, or are intolerant to or progressed on abiraterone acetate. There are two primary study hypotheses.\n\nHypothesis 1: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Overall Survival (OS).\n\nHypothesis 2: The combination of pembrolizumab plus enzalutamide is superior to placebo plus enzalutamide with respect to Radiographic Progression-free Survival (rPFS) per Prostate Cancer Working Group (PCWG)-modified Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as assessed by blinded independent central review."}, "eligibilityModule": {"eligibilityCriteria": "The main inclusion and exclusion criteria include but are not limited to the following:\n\nInclusion Criteria:\n\n* Has histologically- or cytologically-confirmed adenocarcinoma of the prostate without small cell histology\n* Has prostate cancer progression while on androgen deprivation therapy (or post bilateral orchiectomy) within 6 months prior to randomization\n* Has current evidence of metastatic disease documented by either bone lesions on bone scan and/or soft tissue disease by computed tomography/magnetic resonance imaging (CT/MRI)\n* Has met one of the following criteria with regard to abiraterone acetate exposure: (1) is abiraterone-na\u00efve; (2) received prior abiraterone acetate for the treatment of mHSPC or mCRPC, for a minimum of 4 weeks and not progressed while on treatment; or (3) received prior abiraterone acetate for the treatment of mHSPC or mCRPC and progressed on treatment after a minimum of 8 weeks treatment (minimum 14 weeks for those with bone progression)\n* Has ongoing androgen deprivation with serum testosterone \\<50 ng/dL (\\<2.0 nM)\n* Participants receiving bone resorptive therapy (including, but not limited to, bisphosphonate or denosumab) must have been on stable doses prior to randomization\n* Participants must agree to the following during the study treatment period and for at least 90 days after the last dose of enzalutamide: Refrain from donating sperm, plus EITHER be abstinent OR must agree to use male condom\n* Has provided newly obtained core or excisional biopsy (obtained within 12 months of screening) from soft tissue not previously irradiated (samples from tumors progressing in a prior site of radiation are allowed). Participants with bone only or bone predominant disease may provide a bone biopsy sample\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 assessed within 7 days of randomization\n\nExclusion Criteria:\n\n* Has a known additional malignancy that is progressing or has required active treatment in the last 3 years\n* Has an active autoimmune disease that has required systemic treatment in past 2 years\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy\n* Has undergone major surgery including local prostate intervention (excluding prostate biopsy) within 28 days prior to randomization and not recovered adequately from the toxicities and/or complications\n* Has a gastrointestinal disorder affecting absorption or is unable to swallow tablets/capsules\n* Has an active infection (including tuberculosis) requiring systemic therapy\n* Has a history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or current pneumonitis/interstitial lung disease\n* Has known active human immunodeficiency virus (HIV), concurrent active hepatitis B virus (HBV) or known active hepatitis C virus (HCV) infection\n* Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis\n* Has hypersensitivity to pembrolizumab and/or enzalutamide and/or any of their excipients\n* Has a history of seizure or any condition that may predispose to seizure\n* Has a history of loss of consciousness within 12 months of screening\n* Has hypotension (systolic blood pressure \\<86 millimeters of mercury \\[mmHg\\]) or uncontrolled hypertension (systolic blood pressure \\>170 mmHg or diastolic blood pressure \\>105 mmHg) at the screening visit\n* Has bradycardia (heart rate of \\<50 beats per minute) on the screening electrocardiogram (ECG)\n* Has history of prostate cancer progression on ketoconazole\n* Has had prior treatment with enzalutamide, apalutamide, darolutamide or cytochrome P450 (CYP) 17 inhibitor other than abiraterone acetate\n* Has received prior therapy with an anti-programmed cell death-1 (anti-PD-1), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent or with an agent directed to another stimulatory or coinhibitory T-cell receptor\n* Has received prior treatment with radium or other therapeutic radiopharmaceuticals for prostate cancer\n* Has received prior treatment with docetaxel or another chemotherapy agent for mCRPC\n* Has had a prior anti-cancer monoclonal antibody (mAb) prior to randomization\n* Has used herbal products that may have hormonal anti-prostate cancer activity and/or are known to decrease PSA levels (eg, saw palmetto) prior to randomization\n* Has received a live or live attenuated vaccine within 30 days prior to randomization\n* Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the first dose of study treatment\n* Has a \"superscan\" bone scan\n* Is expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 90 days after the last dose of enzalutamide\n* Has had an allogenic tissue/solid organ transplant", "healthyVolunteers": false, "sex": "MALE", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}, {"protocolSection": {"identificationModule": {"nctId": "NCT03426891", "briefTitle": "Pembrolizumab and Vorinostat Combined With Temozolomide for Newly Diagnosed Glioblastoma", "officialTitle": "A Phase I Trial of Pembrolizumab and Vorinostat Combined With Temozolomide and Radiation Therapy for Newly Diagnosed Glioblastoma"}, "descriptionModule": {"briefSummary": "The purpose of this research study is to test the safety and tolerability of the combination treatment of the investigational drugs vorinostat and pembrolizumab, in combination with chemotherapy (temozolomide), and radiotherapy. The U.S. Food and Drug Administration (FDA) has approved pembrolizumab for use to treat a deadly skin cancer called melanoma and lung cancer and vorinostat to treat some forms of blood and lymph node cancers. However, both vorinostat and pembrolizumab are considered investigational drugs in this study because they are not approved for treatment of glioblastoma.", "detailedDescription": "There are 2 parts to this study:\n\nPart 1 (dose escalation) and Part 2 (dose expansion). The main purpose of Part 1 is Dose-Escalation. \"Dose-Escalation\" means that different dose levels will be tested at different times during the study to find the best dose level that is safe and well tolerated in participants. In this study investigators will determine the best dose of Vorinostat that can be given with pembrolizumab, chemotherapy and radiotherapy. The dose of temozolomide and radiotherapy will be the same as standard treatment.\n\nPart 2 (Dose Expansion), all participants will receive the same dose of vorinostat with pembrolizumab, chemotherapy and radiotherapy.\n\nMaintenance Phase: During the maintenance phase, participants will receive Temozolomide (for the first 6 months), vorinostat (for 12 months), and pembrolizumab (for 12 months)."}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Newly diagnosed glioblastoma or gliosarcoma\n* Histologically confirmed diagnosis of World Health Organization Grade IV malignant glioma\n* An interval of \u2265 21 days since surgical resection prior to treatment on the trial\n* Karnofsky performance status of 70 or higher\n* Adequate organ function laboratory values\n* Resting baseline O2 saturation by pulse oximetry of \u2265 92% at rest\n* Willing and able to provide written informed consent/assent for the trial.\n* Life expectancy \u2265 12 weeks\n* Willingness to discontinue medications known to be associated with risk of Torsades de Pointes such as quinidine, procainamide, disopyramide, amiodarone, erythromycin, clarithromycin, chlorpromazine and haloperidol\n* Single lesion \\< 4 cm in longest diameter (diameter of enhancing lesion)\n* Patient shouldn't have received any anti-cancer therapy for glioblastoma in past\n* Females of childbearing potential (FOCBP) should have a negative urine or serum pregnancy prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required.\n* Females and males of childbearing potential must be willing to use an adequate method of contraception per protocol for the course of the study through 120 days after the last dose of study medication. Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for participant.\n* Use of Optune device is allowed.\n\nExclusion Criteria:\n\n* Had prior treatment of glioblastoma (GBM) with radiation and temozolomide\n* Has evidence of leptomeningeal disease\n* Had prior treatment with Gliadel\n* Unable (due to existent medical condition) or unwilling to have a contrast enhanced MRI of brain\n* Currently participating and receiving study therapy or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks of the first dose of treatment\n* Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment. Physiologic doses of steroid therapy (\u2264 2 mg/day dexamethasone equivalents) by the time of first dose of treatment are allowed.\n* Has a known history of active Bacillus Tuberculosis (TB)\n* Hypersensitivity to pembrolizumab or any of its excipients\n* Has had a prior anti-cancer monoclonal antibody (mAb) within 4 weeks prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to agents administered more than 4 weeks earlier\n* Has had prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2 weeks prior to study Day 1 or who has not recovered (i.e., \u2264 Grade 1 or at baseline) from adverse events due to a previously administered agent. Note: Potential participants with \u2264 Grade 2 neuropathy are an exception to this criterion and may qualify for the study. Note: If patient received major surgery, they must have recovered adequately from the toxicity and/or complications from the intervention prior to starting therapy.\n* Has a known additional malignancy that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the skin that has undergone potentially curative therapy or in situ cervical cancer.\n* Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment. Patients with vitiligo or resolved childhood asthma/atopy would be an exception to this rule. Patients that require intermittent use of bronchodilators or local steroid injections would not be excluded from the study. Patients with hypothyroidism stable on hormone replacement or Sjorgen's syndrome will not be excluded from the study.\n* Has known history of, or any evidence of active, interstitial lung disease or non-infectious pneumonitis requiring corticosteroid therapy\n* Has an active serious infection requiring systemic therapy\n* Had major surgical procedure, open biopsy, or significant traumatic injury within 21 days prior to day 1 of treatment on study\n* Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the trial, interfere with the patient's participation for the full duration of the trial, or is not in the best interest of the patient to participate\n* Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial\n* Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n* Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.\n* Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies).\n* Has known active Hepatitis B (e.g., HBsAg reactive) or Hepatitis C (e.g., HCV RNA \\[qualitative\\] is detected).\n* Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (e.g., Flu-Mist\u00ae) are live attenuated vaccines, and are not allowed.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}, {"protocolSection": {"identificationModule": {"nctId": "NCT04579380", "briefTitle": "Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations", "officialTitle": "A Phase 2 Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations"}, "descriptionModule": {"briefSummary": "This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the body (metastatic) or cannot be removed completely with surgery (unresectable).\n\nAll participants will get both tucatinib and trastuzumab. People with hormone-receptor positive breast cancer will also get a drug called fulvestrant.\n\nThe trial will also look at what side effects happen. A side effect is anything a drug does besides treating cancer.", "detailedDescription": "There are multiple cohorts in this trial:\n\n* 5 tumor specific cohorts with HER2 overexpression/amplification (cervical cancer, uterine cancer, biliary tract cancer, urothelial cancer, and non-squamous non-small cell lung cancer \\[NSCLC\\])\n* 2 tumor specific cohorts with HER2 mutations (non-squamous NSCLC and breast cancer)\n* 2 cohorts which will enroll all other HER2 amplified/overexpressed solid tumor types (except breast cancer, gastric or gastroesophageal junction adenocarcinoma \\[GEC\\], and colorectal cancer \\[CRC\\]) or HER2-mutated solid tumor types."}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria\n\n* Histologically or cytologically confirmed diagnosis of locally-advanced unresectable or metastatic solid tumor, including primary brain tumors\n* Participants with non-squamous NSCLC must have progressed during or after standard treatment or for which no standard treatment is available\n* Participants with other disease types must have progressed during or after \u22651 prior line of systemic therapy for locally-advanced unresectable or metastatic disease\n* Disease progression during or after, or intolerance of, the most recent line of systemic therapy\n* Disease demonstrating HER2 alterations (overexpression/amplification or HER2 activating mutations), as determined by local or central testing processed in a Clinical Laboratory Improvement Amendments (CLIA)- or International Organization for Standardization (ISO) accredited laboratory, according to one of the following:\n\n  * HER2 overexpression/amplification from fresh or archival tumor tissue or blood\n  * Known activating HER2 mutations detected in fresh or archival tumor tissue or blood\n* Have measurable disease per RECIST v1.1 criteria according to investigator assessment\n* Have Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n\nExclusion Criteria\n\n* Participants with breast cancer, gastric or gastroesophageal junction adenocarcinoma, or CRC whose disease shows HER2 amplification/overexpression.\n* Previous treatment with HER2-directed therapy; participants with uterine serous carcinoma or HER2-mutated gastric or gastroesophageal junction adenocarcinoma without HER2-overexpression/amplification may have received prior trastuzumab\n* Known hypersensitivity to any component of the drug formulation of tucatinib or trastuzumab (drug substance, excipients, murine proteins), or any component of the drug formulation of fulvestrant in participants with HR+ HER2-mutated breast cancer\n* History of exposure to a 360 mg/m\u00b2 doxorubicin-equivalent or \\>720 mg/m\\^2 epirubicin-equivalent cumulative dose of anthracyclines\n* Treatment with any systemic anti-cancer therapy, radiation therapy, major surgery, or experimental agent within \u22643 weeks of first dose of study treatment or are currently participating in another interventional clinical trial.\n\nThere are additional inclusion and exclusion criteria. The study center will determine if criteria for participation are met.", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}, {"protocolSection": {"identificationModule": {"nctId": "NCT01810913", "briefTitle": "Testing Docetaxel-Cetuximab or the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy and Radiation Therapy in High-Risk Head and Neck Cancer", "officialTitle": "Randomized Phase II/III Trial of Adjuvant Radiation Therapy With Cisplatin, Docetaxel-Cetuximab, or Cisplatin-Atezolizumab in Pathologic High-Risk Squamous Cell Cancer of the Head and Neck"}, "descriptionModule": {"briefSummary": "This phase II/III trial studies how well radiation therapy works when given together with cisplatin, docetaxel, cetuximab, and/or atezolizumab after surgery in treating patients with high-risk stage III-IV head and neck cancer the begins in the thin, flat cells (squamous cell). Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Cetuximab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. The purpose of this study is to compare the usual treatment (radiation therapy with cisplatin chemotherapy) to using radiation therapy with docetaxel and cetuximab chemotherapy, and using the usual treatment plus an immunotherapy drug, atezolizumab.", "detailedDescription": "PRIMARY OBJECTIVES:\n\nI. To select the better docetaxel-based experimental arm to improve disease-free survival (DFS) over the control arm of radiation and cisplatin. (Phase II) (COMPLETE AS OF 20-MAR-2020) II. To determine if the combination of docetaxel-cetuximab and intensity-modulated radiation therapy (IMRT) is superior in terms of overall survival (OS) compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC). (Phase III) III. To determine if the combination of atezolizumab, cisplatin, and IMRT is superior in terms of OS compared to standard cisplatin and IMRT in the adjuvant treatment of pathologic high risk, HPV-negative HNSCC. (Phase III)\n\nSECONDARY OBJECTIVES:\n\nI. To compare disease-free survival (DFS) between each experimental arm and the control arm. (Phase III) II. To determine whether each experimental arm improves local-regional disease control and the rate of distant metastasis. (Phase III) III. To compare acute toxicity profiles between each experimental arm and the control arm. (Phase III) IV. To compare late toxicity profiles at 1, 3, and 5 years after treatment. (Phase III) V. To assess long term DFS and OS between each experimental arm and the control arm. (Phase III) VI. To compare symptom burden, as measured by the MD Anderson Symptom Inventory - Head and Neck (MDASI-HN) (primary patient reported outcome \\[PRO\\]), and quality of life, as measured by the Functional Assessment of Cancer Therapy - Head and Neck (FACT-H\\&N) (secondary PRO), between each experimental arm and the control arm. (Phase III)\n\nEXPLORATORY OBJECTIVE:\n\nI. To collect blood and tissue specimens for future translational research. (Phase III)\n\nOUTLINE: Patients are randomized to 1 of 3 arms - Phase II (Arms 1, 2 or 3) and for Phase III (Arms 1, 3 or 4).\n\nARM 1: Patients undergo intensity modulated radiation therapy (IMRT) once daily (QD) five days a week for 6 weeks and receive concurrent cisplatin intravenously (IV) over 1-2 hours once weekly for 6 weeks.\n\nARM 2: Patients undergo IMRT as in Arm I and receive concurrent docetaxel IV over 60 minutes once weekly for 6 weeks. (CLOSED AS OF 20-MAR-2020)\n\nARM 3: Patients receive cetuximab IV over 120 minutes on week 1 and over 60 minutes once weekly on weeks 2-7. Patients undergo IMRT as in Arm I and concurrently receive docetaxel once weekly for 6 weeks.\n\nARM 4: Patients undergo IMRT QD five days a week for 6 weeks and receive concurrent cisplatin IV over 1-2 hours once weekly for 6 weeks. Starting 1 week before IMRT, patients also receive atezolizumab IV over 30-60 minutes every 3 weeks for up to 8 doses (weeks -1, 3, 6, 9, 12, 15, 18, and 21) in the absence of disease progression and unacceptable toxicity.\n\nAll patients undergo computed tomography (CT) scans and/or magnetic resonance imaging (MRI), and collection of blood during follow-up.\n\nAfter completion of study treatment, patients are followed up at 1 and 3 months, every 3 months for 2 years, every 6 months for 3 years, and then annually thereafter."}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* PHASE II INCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020)\n* Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx\n* Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration; Note: patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within 63 days prior to registration; if, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible\n* Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink)\n* Pathologic stage III or IV HNSCC, including no distant metastases, based upon the following minimum diagnostic workup:\n\n  * General history and physical examination by a radiation oncologist and/or medical oncologist within 84 days prior to registration;\n  * Examination by an ear nose throat (ENT) or head \\& neck surgeon prior to surgery; a laryngopharyngoscopy (mirror and/or fiber optic and/or direct procedure), if appropriate, is recommended but not required; intra-operative examination is acceptable documentation\n  * Pre-operative (op) Imaging of the head and neck: A neck computed tomography (CT) (with contrast) or CT/positron emission tomography (PET) (with contrast) and/or an magnetic resonance imaging (MRI) of the neck (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in Digital Imaging and Communications in Medicine (DICOM) format via TRIAD; the report is to be uploaded into Rave\n  * Chest CT scan (with or without contrast) or CT/PET that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: if the CT/PET with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement\n* Zubrod performance status of 0-1 within 14 days prior to registration\n* Age \\>= 18\n* Absolute granulocyte count (AGC) \\>= 1,500 cells/mm\\^3 (obtained within 14 days prior to registration on study)\n* Platelets \\>= 100,000 cells/mm\\^3 (obtained within 14 days prior to registration on study)\n* Hemoglobin \\>= 8.0 g/dl (Note: the use of transfusion or other intervention to achieve hemoglobin \\[Hgb\\] \\>= 8.0 g/dl is acceptable)\n* Total bilirubin \\< 2 x institutional upper limit of normal (ULN) within 14 days prior to registration\n* Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\< 3 x institutional ULN within 14 days prior to registration\n* Serum creatinine institutional ULN within 14 days prior to registration or; creatinine clearance (CC) \\>= 50 ml/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula\n* Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential\n* The following assessments are required within 14 days prior to registration: sodium (Na), potassium (K), chloride (Cl), glucose, calcium (Ca), magnesium (Mg), and albumin; Note: patients with an initial magnesium \\< 0.5 mmol/L (1.2 mg/dl) may receive corrective magnesium supplementation but should continue to receive either prophylactic weekly infusion of magnesium and/or oral magnesium supplementation (e.g., magnesium oxide) at the investigator's discretion\n* Patients with feeding tubes are eligible for the study\n* Women of childbearing potential and male participants who are sexually active must agree to use a medically effective means of birth control\n* Patient must provide study specific informed consent prior to study entry, including consent for mandatory tissue submission for epidermal growth factor receptor (EGFR) analysis and for oropharyngeal cancer patients, human papilloma virus (HPV) analysis\n* PHASE III: Pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx\n* PHASE III: Patients with oropharyngeal cancer must have p16-negative based on central review prior to Step 2 registration; all patients with oropharyngeal primary must consent for mandatory tissue submission for central p16 confirmation\n* PHASE III: Patients must have undergone gross total surgical resection of high-risk oral cavity, oropharynx (p16 negative), larynx, or hypopharynx within 63 days prior to registration; note: patients may have biopsy under general anesthesia in an operating room followed by definitive ablative cancer surgery representing gross total resection; the gross total resection has to be done within 63 days prior to registration; if, however, patients have ablative resection but shortly recur or are determined to have persisting disease requiring re-resection to achieve gross total resection, then the patient is not eligible\n* PHASE III: Patients must have at least 1 of the following high-risk pathologic features: extracapsular nodal extension or invasive cancer at the primary tumor resection margin (tumor on ink or tumor in a final separately submitted margin)\n* PHASE III: Pathologic stage III or IV HNSCC (American Joint Committee on Cancer \\[AJCC\\] 7th edition), including no distant metastases, based upon the following minimum diagnostic workup:\n\n  * General history and physical examination by a radiation oncologist or medical oncologist within 84 days prior to registration;\n  * Examination by an ENT or head \\& neck surgeon prior to surgery; a laryngopharyngoscopy (mirror or fiberoptic or direct procedure), if appropriate, is recommended but not required. Intra-operative examination is acceptable documentation.\n  * Pre-op Imaging of the head and neck: A neck CT (with contrast and of diagnostic quality) or PET/CT (with contrast and of diagnostic quality) and/or an MRI of the neck of diagnostic quality (T1 with gadolinium and T2) within 84 days prior to surgery; Note: this imaging data (diagnostic pre-operative scan showing gross disease) is to be submitted in DICOM format via TRIAD. The report is to be uploaded into Rave.\n  * Chest CT scan (with or without contrast) or PET/CT that includes the chest (with or without contrast) either within 84 days prior to surgery or within 120 days prior to registration; Note: If the PET/CT with or without contrast is done within 84 days prior to surgery, it fulfills the chest imaging requirement\n* PHASE III: Zubrod performance status of 0-1 within 14 days prior to registration\n* PHASE III: Leukocytes \\>= 2,500 cells/mm\\^3 (obtained within 14 days prior to registration on study)\n* PHASE III: Absolute neutrophil count (ANC) \\>= 1,500 cells/mm\\^3 (obtained within 14 days prior to registration on study)\n* PHASE III: Platelets \\>= 100,000 cells/mm\\^3 (obtained within 14 days prior to registration on study)\n* PHASE III: Hemoglobin \\>= 8.0 g/dL (Note: The use of transfusion or other intervention to achieve Hgb \\>= 8.0 g/dL is acceptable) (obtained within 14 days prior to registration on study)\n* PHASE III: Total bilirubin =\\< 1.5 x institutional upper limit of normal (ULN) (however, patients with known Gilbert disease who have serum bilirubin level =\\< 3 x institutional ULN may be enrolled) (within 14 days prior to registration)\n* PHASE III: AST or ALT =\\< 3 x institutional ULN (within 14 days prior to registration)\n* PHASE III: Alkaline phosphatase =\\< 2.5 x institutional ULN (within 14 days prior to registration)\n* PHASE III: Creatinine clearance (CrCl) \\>= 50 mL/min within 14 days prior to registration determined by 24-hour collection or estimated by Cockcroft-Gault formula\n* PHASE III: Patients with feeding tubes are eligible for the study\n* PHASE III: Negative urine or serum pregnancy test within 14 days prior to registration for women of childbearing potential\n* PHASE III: All patients must provide study specific informed consent prior to study entry\n* PHASE III: Patients positive for human immunodeficiency virus (HIV) are allowed on study, but HIV-positive patients must have:\n\n  * A stable regimen of highly active anti-retroviral therapy (HAART);\n  * No requirement for concurrent antibiotics or antifungal agents for the prevention of opportunistic infections;\n  * A CD4 count above 250 cells/mcL and an undetectable HIV viral load on standard polymerase chain reaction (PCR)-based tests\n\nExclusion Criteria:\n\n* PHASE II EXCLUSION CRITERIA (COMPLETE AS OF 20-MAR-2020)\n* Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years); noninvasive cancers (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) are permitted even if diagnosed and treated \\< 3 years ago\n* Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible\n* Prior systemic chemotherapy or anti-epidermal growth factor (EGF) therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable\n* Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\n* Severe, active co-morbidity, defined as follows:\n\n  * Unstable angina and/or congestive heart failure requiring hospitalization within 6 months prior to registration\n  * Transmural myocardial infarction within 6 months prior to registration\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\n\n    * Idiopathic pulmonary fibrosis or other severe interstitial lung disease that requires oxygen therapy or is thought to require oxygen therapy within 1 year prior to registration\n  * Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects; note, however, that laboratory tests for coagulation parameters are not required for entry into this protocol\n\n    * Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease and Control and Prevention (CDC) definition; note: human immunodeficiency virus (HIV) testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive; protocol-specific requirements may also exclude immuno-compromised patients.\n* Grade 3-4 electrolyte abnormalities (Common Terminology Criteria for Adverse Events \\[CTCAE\\], version \\[v.\\] 4):\n* Serum calcium (ionized or adjusted for albumin) \\< 7 mg/dl (1.75 mmol/L) or \\> 12.5 mg/dl (\\> 3.1 mmol/L) despite intervention to normalize levels\n* Glucose \\< 40 mg/dl (\\< 2.2 mmol/L) or \\> 250 mg/dl (\\> 14 mmol/L)\n* Magnesium \\< 0.9 mg/dl (\\< 0.4 mmol/L) or \\> 3 mg/dl (\\> 1.23 mmol/L) despite intervention to normalize levels\n* Potassium \\< 3.0 mmol/L or \\> 6 mmol/L despite intervention to normalize levels\n* Sodium \\< 130 mmol/L or \\> 155 mmol/L despite intervention to normalize levels\n* Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic\n* Prior allergic reaction to cetuximab\n* PHASE III: Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 1095 days (3 years) with the following exceptions: T1-2, N0, M0 resected differentiated thyroid carcinoma; Note that noninvasive cancers (For example, carcinoma in situ of the breast, oral cavity, or cervix) are permitted even if diagnosed and treated \\< 3 years ago\n* PHASE III: Patients with simultaneous primaries or bilateral tumors are excluded, with the exception of patients with bilateral tonsil cancers or patients with T1-2, N0, M0 resected differentiated thyroid carcinoma, who are eligible\n* PHASE III: Prior systemic therapy, including cytotoxic chemotherapy, biologic/targeted therapy (such as anti-EGF therapy), or immune therapy for the study cancer; note that prior chemotherapy for a different cancer is allowable, however, a prior anti-PD-1, anti-PD-L1, or anti-PD-L2 agent is not permitted\n* PHASE III: Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields\n* PHASE III: Severe, active co-morbidity, defined as follows:\n\n  * Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification; to be eligible for this trial, patients should be class 2B or better within 6 months prior to registration\n  * Transmural myocardial infarction within 6 months prior to registration;\n  * Severe infections within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia;\n  * Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration; Note: Patients receiving prophylactic antibiotics (e.g., for prevention of a urinary tract infection or chronic obstructive pulmonary disease exacerbation) are eligible.\n  * Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration;\n  * History of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan. History of radiation pneumonitis in a prior radiation field (fibrosis) is permitted, provided that field does not overlap with the planned radiation field for the study cancer;\n  * Patients with active tuberculosis (TB) are excluded;\n  * Known clinically significant liver disease, including active viral, alcoholic, or other hepatitis; cirrhosis; fatty liver; and inherited liver disease;\n\n    * Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \\[HBsAg\\] test and a positive anti-HBc \\[antibody to hepatitis B core antigen\\] antibody test) are eligible.\n    * Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for HCV RNA.\n  * History of allogeneic bone marrow transplantation or solid organ transplantation.\n  * A diagnosis of immunodeficiency:\n\n    * Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note: HIV testing is not required for entry into this protocol; the need to exclude patients with AIDS from this protocol is necessary because the treatments involved in this protocol may be significantly immunosuppressive.\n  * Is receiving treatment with systemic immunosuppressive medications (including, but not limited to, prednisone, cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor \\[anti-TNF\\] agents) within 2 weeks prior to registration.\n\n    * Note: Patients who have received acute, low dose, systemic immunosuppressant medications (e.g., a one-time dose of dexamethasone for nausea) may be enrolled.\n    * Note: The use of inhaled corticosteroids and mineralocorticoids (e.g., fludrocortisone) for patients with orthostatic hypotension or adrenocortical insufficiency is allowed.\n  * History or risk of autoimmune disease, including, but not limited to, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, vascular thrombosis associated with antiphospholipid syndrome, Wegener's granulomatosis, Sjogren's syndrome, Guillain-Barr\u00e9 syndrome, multiple sclerosis, vasculitis, or glomerulonephritis.\n\n    * Patients with a history of autoimmune hypothyroidism who are asymptomatic and/or are on a stable dose of thyroid replacement hormone are eligible.\n    * Patients with controlled Type 1 diabetes mellitus on a stable insulin regimen are eligible.\n    * Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis would be excluded) are permitted provided that they meet the following conditions:\n    * Patients with psoriasis must have a baseline ophthalmologic exam to rule out ocular manifestations\n    * Rash must cover less than 10% of body surface area (BSA)\n    * Disease is well controlled at baseline and only requiring low potency topical steroids (e.g., hydrocortisone 2.5%, hydrocortisone butyrate 0.1%, flucinolone 0.01%, desonide 0.05%, aclometasone dipropionate 0.05%)\n    * No acute exacerbations of underlying condition within the last 12 months (not requiring psoralen plus ultraviolet A radiation \\[PUVA\\], methotrexate, retinoids, biologic agents, oral calcineurin inhibitors; high potency or oral steroids)\n* PHASE III: Grade 3-4 electrolyte abnormalities (CTCAE, v. 4) within 14 days prior to registration:\n\n  * Serum calcium (ionized or adjusted for albumin) \\< 7 mg/dL (1.75 mmol/L) or \\> 12.5 mg/dL (\\> 3.1 mmol/L) despite intervention to normalize levels;\n  * Glucose \\< 40 mg/dL (\\< 2.2 mmol/L) or \\> 250 mg/dL (\\> 14 mmol/L);\n  * Magnesium \\< 0.9 mg/dL (\\< 0.4 mmol/L) or \\> 3 mg/dL (\\> 1.23 mmol/L) despite intervention to normalize levels;\n  * Potassium \\< 3.0 mmol/L or \\> 6 mmol/L despite intervention to normalize levels;\n  * Sodium \\< 130 mmol/L or \\> 155 mmol/L despite intervention to normalize levels.\n* PHASE III: Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception for up to 5 months from last study treatment; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic. Women who are breastfeeding and unwilling to discontinue are also excluded\n* PHASE III: History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* PHASE III: Patients taking bisphosphonate therapy for symptomatic hypercalcemia. Use of bisphosphonate therapy for other non-oncologic reasons (e.g., osteoporosis) is allowed\n* PHASE III: Patients requiring treatment with a RANKL inhibitor (e.g. denosumab) for non-oncologic reasons who cannot discontinue it before registration\n* PHASE III: Patients with known distant metastatic disease are excluded\n* PHASE III: Known hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies\n* PHASE III: Major surgical procedure within 28 days prior to registration or anticipation of need for a major surgical procedure during the course of the study\n* PHASE III: Administration of a live, attenuated vaccine within 4 weeks prior to registration or anticipation that such a live, attenuated vaccine will be required during the study and for patients receiving atezolizumab, up to 5 months after the last dose of atezolizumab.\n\n  * Influenza vaccination should be given during influenza season only (approximately October to March). Patients must not r", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}, {"protocolSection": {"identificationModule": {"nctId": "NCT04511013", "briefTitle": "A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases", "officialTitle": "A Randomized Phase 2 Trial of Encorafenib + Binimetinib + Nivolumab vs Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases"}, "descriptionModule": {"briefSummary": "This phase II trial compares the effect of encorafenib, binimetinib, and nivolumab versus ipilimumab and nivolumab in treating patients with BRAF- V600 mutant melanoma that has spread to the brain (brain metastases). Encorafenib and binimetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ipilimumab and nivolumab are monoclonal antibodies that may interfere with the ability of tumor cells to grow and spread. This trial aims to find out which approach is more effective in shrinking and controlling brain metastases from melanoma.", "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To compare progression-free survival (PFS) per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 between participants randomized to the triplet combination of encorafenib + binimetinib + nivolumab versus the doublet combination of ipilimumab + nivolumab among participants with BRAF-V600 mutant melanoma that has metastasized to the brain.\n\nSECONDARY OBJECTIVES:\n\nI. To estimate the overall survival (OS) of participants in each treatment arm. II. To estimate the objective response rate (ORR) (confirmed and unconfirmed, complete and partial responses) per RECIST 1.1 in each treatment arm.\n\nIII. To estimate the intracranial response rate (ICRR), defined as confirmed and unconfirmed complete and partial response per modified RECIST for brain metastases (mRECIST).\n\nIV. To evaluate the duration of response, per RECIST 1.1 and the duration of ICRR per mRECIST, and per Response Assessment in Neuro-Oncology (RANO)-Brain Metastases (BM) (and immunotherapy \\[i\\]RANO) in each treatment arm.\n\nV. To evaluate the toxicity profile of each treatment arm. VI. To evaluate current and emerging radiographic response criteria (modified RECIST 1.1, modified RANO-BM and iRANO) by a retrospective blinded independent centralized review (BICR) of banked images.\n\nBANKING OBJECTIVE:\n\nI. To bank tumor tissue, cerebral spinal fluid (CSF), stool and blood samples for future correlative studies.\n\nOUTLINE: Patients are randomized to 1 of 2 arms.\n\nARM I: Patients receive encorafenib orally (PO) once daily (QD) on days 1-28, binimetinib PO twice daily (BID) on days 1-28, and nivolumab intravenously (IV) on day 1. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.\n\nARM II: Patients receive nivolumab IV on day 1 of all cycles and ipilimumab IV over 30 minutes on day 1 of cycles 1-4. Cycles repeat every 21 days for 4 cycles and then every 28 days in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed up every 6 months for 2 years, and then annually until 3 years after randomization."}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Participants must have histologically and pathologically confirmed melanoma that has metastasized to the brain\n* Any primary (cutaneous, acral/mucosal, etc) or unknown origin are permitted, except that participants with uveal primary are not eligible\n* Participants must have BRAF-V600 mutant melanoma documented by a Clinical Laboratory Improvement Act (CLIA)-certified laboratory\n* All participants must have an magnetic resonance imaging (MRI) of the brain within 28 days prior to registration and must have central nervous system metastases with at least one measurable brain metastasis \\>= 0.5 cm in size (per modified RECIST 1.1) that has not been irradiated, or progressed (in the opinion of the treating physician) after prior radiation therapy. Participating sites MUST use MRI slice thickness of =\\< 1.5 mm and are recommended to adhere to the 'minimum' Brain Tumor Imaging Protocol for Clinical Trials in Brain Metastases (BTIP-BM) compliant MRI acquisition protocol. Computed tomography (CT) of the head cannot substitute for brain MRI. (NOTE: All central nervous system \\[CNS\\] disease must be documented on BOTH the Brain Metastases Baseline Tumor Assessment Form, using modified RECIST, and the Baseline Tumor Assessment Form \\[RECIST 1.1\\] using RECIST 1.1.)\n* Participants may have measurable or non-measurable extracranial disease. All measurable disease must be assessed within 28 days prior to randomization; all non-measurable disease must be assessed within 42 days prior to randomization. Please note, while any extracranial disease will also be assessed and followed, participants are NOT required to have extracranial disease for randomization. NOTE: All disease must be assessed and documented on the Baseline Tumor Assessment Form (RECIST 1.1). CNS disease must be documented on BOTH the Brain Metastases Baseline Tumor Assessment Form, using modified RECIST, and the Baseline Tumor Assessment Form (RECIST 1.1) using RECIST 1.1\n* Participants may have leptomeningeal disease\n* Participants may be receiving corticosteroids for brain metastases at a dose of up to 8 mg of dexamethasone per day. The dose must not have exceeded 8 mg per day for at least 7 days prior to randomization\n* Participants must have Zubrod performance status =\\< 2\n* Participants must have complete history and physical examination within 28 days prior to randomization\n* Participants must be able to swallow and retain pills\n* Hemoglobin \\>= 8.0 g/dL (within 28 days prior to randomization)\n* Absolute neutrophil count \\>= 1,500/mcL (within 28 days prior to randomization)\n* Platelets \\>= 75,000/mcL (within 28 days prior to randomization)\n* Total bilirubin =\\< 1.5 institutional upper limit of normal (ULN) (within 28 days prior to randomization)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\< 2.5 x institutional ULN (in participants with liver metastases =\\< 5 x ULN) (within 28 days prior to randomization)\n* Creatinine =\\< 2.0 institutional ULN (within 28 days prior to randomization)\n* Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, participants must be class 2B or better\n* Participants with a prior or concurrent malignancy whose natural history or treatment (in the opinion of the treating physician) does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial\n* Participants with known human immunodeficiency virus (HIV)-infection are eligible providing they are on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 90 days prior to randomization\n* Participants with a known history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with HCV infection who are currently on treatment must have an undetectable HCV viral load prior to randomization\n* Participants must agree to participate in image banking. Images must be submitted via the Triad System\n* Participants must be offered the opportunity to participate in specimen and blood collections\n* Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines\n* As a part of the OPEN registration process the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system\n\nExclusion Criteria:\n\n* Participants must not have received prior systemic therapy for metastatic disease. Prior systemic therapy received only in the neoadjuvant and/or adjuvant setting (e.g., BRAF/MEK inhibitor therapy, anti-PD-1 therapy or anti-CTLA4 therapy, alfa-interferon, etc.) is permitted. If patients received prior neoadjuvant/adjuvant therapy, they must have had eventual disease relapse prior to randomization\n* Participants must not have had prior radiation therapy within 7 days prior to randomization\n* Participants must not be planning to require any additional form of systemic anti-tumor therapy for melanoma while on protocol treatment\n* Participants must not be planning to use hormonal contraceptives\n* Participants must not have a serious active infection requiring systemic therapy at time of randomization in the opinion of the treating physician\n* Participants must not have active autoimmune disease that has required treatment in the past 6 months with use of biologic disease modifying agents (.e.g. infliximab, adalimumab). Patients on non-biologic disease modifying agents (e.g. methotrexate) or patients on corticosteroids =\\< 10 mg prednisone daily or equivalent (to treat auto-immune disease), or on replacement therapy (e.g., thyroxine, insulin) are eligible if deemed in the best interest of the patient by treating physician\n* Participants must not have had grade 3 or 4 immune-related adverse events on ipilimumab or nivolumab that required more than 12 weeks of immune suppression with corticosteroids\n* Participants must not have had adverse events related to encorafenib and/or binimetinib specifically, that required discontinuation of one or both drugs. (Please note this does not apply to other BRAF/MEK inhibitor drugs.)\n* Participants must not be pregnant or nursing. Women/men of reproductive potential must have agreed to use an effective method of contraception. (NOTE: Patients must agree to not use hormonal contraceptives, as encorafenib can result in decreased concentration and loss of efficacy.) A woman is considered to be of \"reproductive potential\" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, \"effective contraception\" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}, {"protocolSection": {"identificationModule": {"nctId": "NCT04614103", "briefTitle": "Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer", "officialTitle": "A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer"}, "descriptionModule": {"briefSummary": "This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer", "detailedDescription": "LN-145 is a ready-to-infuse TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC. The cell transfer therapy used in this study involves patients receiving a non-myeloablative (NMA) lymphodepleting preparative regimen, followed by infusion of autologous TIL, then finally followed by the administration of IL-2."}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who are over 70 years of age may be allowed to enroll after consultation with the Medical Monitor.\n* Have historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS genomic alterations.\n* For patients who have actionable mutations (other than EGFR, ALK, or ROS genomic alterations), 1 additional line of therapy with the appropriate targeted therapy will be allowed.\n* Patients must have documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and platinum-based chemotherapy \u00b1 bevacizumab. No more than 1 prior line is allowed if ICI and platinum-based chemotherapy were administered concurrently and no more than 2 prior lines are allowed for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines.\n* LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination and meet all eligibility criteria except documented disease progression. These patients must intend to receive TIL therapy after disease progression\n* Prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy, will count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy.\n* At least 1 resectable lesion for TIL production and at least one remaining measurable lesion, as defined by RECIST v1.1\n* Have adequate organ function\n* LVEF \\> 45%, NYHA Class 1\n* Have adequate pulmonary function\n* ECOG performance status of 0 or 1\n* Patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy\n\nExclusion Criteria:\n\n* Patients who have EGFR, ALK or ROS driver mutations\n* Patients who have symptomatic, untreated brain metastases.\n* Patients who have had allogeneic organ transplant or prior cell therapy within the past 20 years\n* Patients who have any form of primary immunodeficiency\n* Patients who are on systemic steroid therapy \u2265 10 mg/day of prednisone or equivalent.\n* Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment\n* Patients who have had another primary malignancy within the previous 3 years\n* Participation in another interventional clinical study within 21 days", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}, {"protocolSection": {"identificationModule": {"nctId": "NCT04671667", "briefTitle": "Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma", "officialTitle": "A Phase II Randomized Trial of Adjuvant Therapy With Pembrolizumab After Resection of Recurrent/Second Primary Head and Neck Squamous Cell Carcinoma With High Risk Features"}, "descriptionModule": {"briefSummary": "This phase II trial studies the effect of pembrolizumab alone compared to the usual approach (chemotherapy \\[cisplatin and carboplatin\\] plus radiation therapy) after surgery in treating patients with head and neck squamous cell carcinoma that has come back (recurrent) or patients with a second head and neck cancer that is not from metastasis (primary). Radiation therapy uses high energy radiation or protons to kill tumor cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Carboplatin is also in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer and may interfere with the ability of tumor cells to grow and spread. Giving pembrolizumab alone after surgery may work better than the usual approach in shrinking recurrent or primary head and neck squamous cell carcinoma.", "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To evaluate overall survival (OS) of adjuvant pembrolizumab for 12 months compared to adjuvant reirradiation plus concurrent platinum chemotherapy in high risk head and neck squamous cell carcinoma (HNSCC) patients.\n\nSECONDARY OBJECTIVES:\n\nI. To evaluate the following endpoints in both arms: disease free survival (DFS), locoregional control, rates of distant metastasis, toxicity.\n\nII. To evaluate whether high PD-L1 expression (defined as Combined Positive Score \\[CPS\\] \\>= 20) is predictive of increased efficacy in the experimental group compared to control.\n\nOUTLINE: Patients are randomized to 1 of 2 arms.\n\nARM B: Patients receive cisplatin or carboplatin intravenously (IV) on day 1. Treatment repeats every 7 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy (PBRT) once daily (QD) for a total of 30 fractions in the absence of disease progression or unacceptable toxicity.\n\nARM C: Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 6 weeks for 9 cycles in the absence of disease progression or unacceptable toxicity.\n\nPatients in all arms undergo computed tomography (CT) or magnetic resonance imaging (MRI) throughout the trial.\n\nAfter completion of study treatment, patients are followed up at 30 days, and then every 6 months for up to 5 years from the date of registration."}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patient must be between 18 and 79 years of age\n* Patient must have locoregionally recurrent or second primary HNSCC (oral cavity, oropharynx, larynx, hypopharynx) in a previously radiated field\n* Patient must have undergone surgery with gross total resection and must be randomized within 8 weeks of surgery\n* Patients must have high risk disease defined as:\n\n  * Positive margins and/or extra nodal extension (ENE)\n\n    * Positive margins are defined as malignancy at or within 1 mm of the margin. High grade dysplasia (i.e. carcinoma in situ) at the margin is also considered positive\n    * ENE may be either gross or microscopic\n* Patient must have a PD-L1 Combined Positive Score (CPS) \\>= 1 in a Clinical Laboratory Improvement Act (CLIA) certified laboratory. Testing can be done locally as long as it is done in a CLIA certified laboratory. This testing must be on the tumor specimen from the resection of the patient's recurrent or second primary HNSCC\n* Patient must have had prior radiation to the area of recurrent or second primary tumor. This is defined as \\> 50% of the presurgical tumor volume having previously received a dose of \\> 45 Gy as determined by the treating radiation oncologist\n* Patient must have completed prior radiation a minimum of 6 months prior to randomization\n* Patient must not have any evidence of distant disease based on baseline imaging done within 28 days prior to randomization\n* Patient must not have received anti-PD-1/PD-L1 therapy for recurrent disease. If the patient received anti-PD-1/PD-L1 therapy as part of initial upfront curative intent treatment (either as part of definitive non-surgical therapy or in the adjuvant setting) in the past, the last dosage of anti-PD-1/PD-L1 therapy must have been given greater than one year prior to randomization\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n* Patient must have the ability to understand and the willingness to sign a written informed consent document. Patients with impaired decision-making capacity (IDMC) who have a legally authorized representative (LAR) or caregiver and/or family member available will also be considered eligible\n* Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used. All patients of childbearing potential must have a blood test or urine study within 14 days prior to randomization to rule out pregnancy. A urine or serum pregnancy test must be repeated within 72 hours prior to receiving the first dose of pembrolizumab or chemotherapy if the test done for eligibility/randomization is done outside of this 72 hour window. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be required. A patient of childbearing potential is defined as anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* Patient must not expect to conceive or father children by using by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse while on study treatment, and continue for 120 days after the last dose of study treatment\n* Absolute neutrophil count (ANC) \\>= 1,500/mcL (obtained =\\< 28 days prior to protocol randomization)\n* Platelets \\>= 100,000/mcL (obtained =\\< 28 days prior to protocol randomization)\n* Total bilirubin =\\< 1.5 x institutional upper limit of normal (ULN) (obtained =\\< 28 days prior to protocol randomization)\n* Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \\[SGOT\\])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase \\[SGPT\\]) =\\< 3.0 x institutional ULN (obtained =\\< 28 days prior to protocol randomization)\n* Creatinine clearance \\> 30 ml/min using the Cockcroft-Gault formula (obtained =\\< 28 days prior to protocol randomization)\n* Patient must not have a current active infection that requires systemic treatment at time of randomization\n* Patient must not have a history of non-infectious pneumonitis requiring steroids within 3 years prior to randomization\n* Patient must not have a history of solid organ transplant or stem cell transplant\n* Patient must not be on immunosuppressive medication within 7 days prior to randomization, EXCEPT for the following: a) intranasal, inhaled, topical steroids, or local steroid injection (e.g., intra-articular injection); b) systemic corticosteroids at physiologic doses =\\< 10 mg/day of prednisone or equivalent; c) steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n* Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional classification. Patients with New York Heart Association class III or IV heart failure are not eligible\n* Patient must not have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guerin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist \\[registered trademark\\]) are live attenuated vaccines and are not allowed\n* Patient must not have severe hypersensitivity (\\>= grade 3) to pembrolizumab and/or any of its excipients\n* Patient must not have an active autoimmune disease that has required systemic treatment in past 2 years (i.e., with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed\n* Patient must not have a known psychiatric or substance abuse disorder that would interfere with the participant's ability to cooperate with the requirements of the study\n* Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months are eligible for this trial as long as they have not been HIV-infected with a history of Kaposi sarcoma and/or multicentric Castleman disease\n* Patient must not have a known history of hepatitis B (defined as hepatitis B surface antigen \\[HBsAg\\] reactive) or known active hepatitis C virus (defined as HCV ribonucleic acid \\[RNA\\] \\[qualitative\\] is detected) infection\n\n  * NOTE: No testing for hepatitis B and hepatitis C is required unless mandated by a local health authority", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "79 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}, {"protocolSection": {"identificationModule": {"nctId": "NCT04614103", "briefTitle": "Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer", "officialTitle": "A Phase 2 Multicenter Study of Autologous Tumor Infiltrating Lymphocytes (TIL or LN-145) in Patients With Metastatic Non-Small-Cell Lung Cancer"}, "descriptionModule": {"briefSummary": "This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer", "detailedDescription": "LN-145 is a ready-to-infuse TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC. The cell transfer therapy used in this study involves patients receiving a non-myeloablative (NMA) lymphodepleting preparative regimen, followed by infusion of autologous TIL, then finally followed by the administration of IL-2."}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Patients who are over 70 years of age may be allowed to enroll after consultation with the Medical Monitor.\n* Have historically or pathologically confirmed diagnosis of metastatic Stage IV NSCLC without EGFR, ALK, or ROS genomic alterations.\n* For patients who have actionable mutations (other than EGFR, ALK, or ROS genomic alterations), 1 additional line of therapy with the appropriate targeted therapy will be allowed.\n* Patients must have documented radiographic disease progression on or after the first-line therapy, including concurrent or sequential ICI and platinum-based chemotherapy \u00b1 bevacizumab. No more than 1 prior line is allowed if ICI and platinum-based chemotherapy were administered concurrently and no more than 2 prior lines are allowed for sequential administration of platinum-based chemotherapy and ICI as 2 separate lines.\n* LN-145 manufacture is allowed for patients who have residual resectable disease after completion of the platinum-based chemotherapy component of the front-line ICI and platinum-based chemotherapy combination and meet all eligibility criteria except documented disease progression. These patients must intend to receive TIL therapy after disease progression\n* Prior systemic therapy in the adjuvant or neoadjuvant setting, or as part of definitive chemoradiotherapy, will count as a line of therapy if the patient had disease progression during or within 12 months after the completion of such therapy.\n* At least 1 resectable lesion for TIL production and at least one remaining measurable lesion, as defined by RECIST v1.1\n* Have adequate organ function\n* LVEF \\> 45%, NYHA Class 1\n* Have adequate pulmonary function\n* ECOG performance status of 0 or 1\n* Patients of childbearing potential or those with partners of childbearing potential must be willing to practice an approved method of highly effective birth control during treatment and up to 12 months after all protocol-related therapy\n\nExclusion Criteria:\n\n* Patients who have EGFR, ALK or ROS driver mutations\n* Patients who have symptomatic, untreated brain metastases.\n* Patients who have had allogeneic organ transplant or prior cell therapy within the past 20 years\n* Patients who have any form of primary immunodeficiency\n* Patients who are on systemic steroid therapy \u2265 10 mg/day of prednisone or equivalent.\n* Patients who have received a live or attenuated vaccination within 28 days prior to the start of treatment\n* Patients who have had another primary malignancy within the previous 3 years\n* Participation in another interventional clinical study within 21 days", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "70 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}, {"protocolSection": {"identificationModule": {"nctId": "NCT04092283", "briefTitle": "Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer", "officialTitle": "Randomized Phase III Trial of MEDI4736 (Durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC"}, "descriptionModule": {"briefSummary": "This phase III trial studies how well an antibody (durvalumab) with chemotherapy and radiation therapy (chemoradiation) works in treating patients with stage III non-small cell lung cancer that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as durvalumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This study is being done to see if adding durvalumab to standard chemoradiation followed by additional durvalumab can extend patients life and/or prevent the tumor from coming back compared to the usual approach of chemoradiation alone followed by durvalumab.", "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To evaluate whether there is an improvement in overall survival with concomitant chemotherapy/radiation therapy/MEDI4736 (durvalumab) followed by one year (12 cycles) of MEDI4736 (durvalumab) as compared to concomitant chemotherapy/radiation followed by one year (12 cycles) of MEDI4736 (durvalumab).\n\nSECONDARY OBJECTIVES:\n\nI. To evaluate the difference in response using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria to assess whether or not MEDI4736 (durvalumab) added to concomitant chemo/radiation results in an improvement in response rates.\n\nII. To evaluate any difference in progression free survival (PFS) with concomitant chemotherapy/radiation therapy/MEDI4736 (durvalumab) followed by one year (12 cycles) of MEDI4736 (durvalumab) as compared to concomitant chemotherapy/radiotherapy followed by one year of MEDI4736 (durvalumab).\n\nIII. To evaluate whether the incidence of recurrence and recurrence pattern is affected by giving MEDI4736 (durvalumab) during chemo/radiation.\n\nIV. To evaluate any difference in toxicity when MEDI4736 (durvalumab) is added to concomitant chemo/radiation using the Common Terminology Criteria for Adverse Events (CTCAE).\n\nOUTLINE:\n\nSTEP 1 (CONCURRENT THERAPY): Patients are randomized to 1 of 2 arms.\n\nARM A: Patients receive durvalumab intravenously (IV) over 60 minutes on days 1 and 15 of cycle 1 and day 1 of cycle 2. Patients also receive 1 of 3 treatment regimens per investigator choice: 1) etoposide IV over 60 minutes on days 1-5 and cisplatin IV over 60 minutes on days 1 and 8 every 28 days for 2 cycles; 2) pemetrexed disodium IV over 60 minutes and cisplatin IV over 60-120 minutes on day 1 every 21 days for 2 cycles; or 3) paclitaxel IV over 60 minutes and carboplatin IV over 30 minutes on day 1 every 7 days for 6 cycles. Treatment continues in the absence of disease progression or unacceptable toxicity. Beginning on day 1 of chemotherapy, patients receive radiation therapy 5 days a week for 6 weeks.\n\nARM B: Patients receive 1 of 3 investigator's choice treatment regimens and radiation therapy as in Arm A.\n\nSTEP 2 (CONSOLIDATION THERAPY): Within 14 days after the last dose of radiation (from Step 1), all patients then receive durvalumab IV over 60 minutes on day 1. Treatment repeats every 28 days for 12 cycles in the absence of disease progression or unacceptable toxicity.\n\nAfter completion of study treatment, patients are followed up every 3 months if less than 2 years from study entry, every 6 months if 2-5 years from study entry, and then yearly for years 5-10 from study entry."}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* STEP 1 INCLUSION ELIGIBILITY CRITERIA - CONCURRENT THERAPY\n* Patient must be \\>= 18 years old\n* Patient must have one of the following:\n\n  * Newly diagnosed stage IIIA/B/C non-small cell lung cancer (NSCLC) (per the American Joint Committee on Cancer \\[AJCC\\] 8th edition) that is unresectable and is histologically and/or cytologically confirmed\n  * Nodal recurrence after surgery for early stage NSCLC\n* Patient must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1\n* Patient must have a body weight \\> 30 kg\n* Patient must not have unintentional weight loss \\> 10% within 30 days prior to registration\n* Patient must have a baseline electrocardiography (ECG) obtained within 6 weeks prior to registration\n* Patient must have measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1. Baseline imaging assessments and measurements used to evaluate all measurable or non-measurable sites of disease must be done within 4 weeks prior to registration\n* Absolute neutrophil count (ANC) \\>= 1500 cells/uL (obtained =\\< 7 days prior to registration)\n* White blood cells (WBC) counts \\>= 2500/uL (obtained =\\< 7 days prior to registration)\n* Platelet count \\>= 100,000/uL (obtained =\\< 7 days prior to registration)\n* Hemoglobin \\>= 9.0 g/dL (obtained =\\< 7 days prior to registration)\n* Total bilirubin =\\< 1.5 x institutional upper limit of normal (ULN) with the following exception: patients with known Gilbert disease who have serum bilirubin level \\< 3 x ULN may be enrolled (obtained =\\< 7 days prior to registration)\n* Aspartate aminotransferase (AST) and alanine transaminase (ALT) =\\< 3.0 x institutional ULN (obtained =\\< 7 days prior to registration)\n* Serum creatinine =\\< 1.5 x institutional ULN or creatinine clearance \\>= 45 mL/min on the basis of the Cockcroft-Gault glomerular filtration rate estimation (obtained =\\< 7 days prior to registration)\n* Patient must have pulmonary function tests (PFTs) with both forced expiratory volume in 1 second (FEV1) and diffusion capacity of the lung for carbon monoxide (DLCO) \\>= 40% of predicted, obtained within 5 months prior to registration\n* Patient is expected to have lung volume (V)20 of =\\< 35%, after radiation oncologist views pre-treatment work up\n* Patients with nodal recurrence after surgery for early-stage NSCLC are eligible if the following criteria are met:\n\n  * No prior chemotherapy or radiation was ever administered for this lung cancer originally or for recurrence prior to entering this protocol\n  * Prior curative-intent surgery was at least 90 days prior to the nodal recurrence\n  * No prior radiation was administered to the region of study cancer that would cause overlap of treatment fields\n* Patients who are human immunodeficiency virus (HIV) positive may participate in the study IF they meet all of the following eligibility requirements:\n\n  * They must be stable on their anti-retroviral regimen, and they must be healthy from an HIV perspective\n  * They must have a CD4 count of greater than 250 cells/mcL, obtained within 6 months prior to registration\n  * They must not be receiving prophylactic therapy for an opportunistic infection\n* Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial. Patients must not have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to registration\n* Patient must not be pregnant or breast-feeding due to the potential harm to an unborn fetus and possible risk for adverse events in nursing infants with the treatment regimens being used.\n* All patients of childbearing potential must have a negative blood test or urine study, with a minimum sensitivity 50 mlU/L or equivalent units of HCG, within 7 days prior to registration to rule out pregnancy. A patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has achieved menarche at some point, 2) has not undergone a hysterectomy or bilateral oophorectomy; or 3) has not been naturally postmenopausal (amenorrhea following cancer therapy does not rule out childbearing potential) for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months).\n* Patients must not expected to conceive or father children by using accepted and highly effective method(s) of contraception during sexual intercourse for at least one week prior to the start of treatment, during protocol treatment, and continue for 90 days after the last dose of protocol treatment.\n\n  * Highly effective methods of contraception include Etonogestrel-releasing implants (Implanon or Norplant), Intravaginal: Ethinylestradiol/etonogestrel-releasing intravaginal devices: e.g., NuvaRing, injection: Medroxyprogesterone injection: e.g., Depo-Provera, combined pill: Normal and low dose combined oral contraceptive pill, patch: Norelgestromin/ethinylestradiol-releasing transdermal system: e.g., Ortho Evra, Minipillc: Progesterone based oral contraceptive pill using desogestrel: Cerazette is currently the only highly effective progesterone based pill\n  * Methods that are considered inadequate include male or female condom with or without spermicide; female cap, diaphragm, or sponge with or without spermicide; non-copper containing intrauterine device; progestogen-only oral hormonal contraceptive pills where inhibition of ovulation is not the primary mode of action \\[excluding Cerazette/desogestrel which is considered highly effective\\]; and triphasic combined oral contraceptive pills)\n* STEP 2 INCLUSION ELIGIBILITY CRITERIA - CONSOLIDATION\n* Patients with any \\> grade 2 non-hematologic or \\> grade 3 hematologic toxicities must recover to grade 2 (or less) within 45 days after the end of Step 1 concurrent chemo/radiation, with the exception of alopecia and vitiligo\n\nExclusion Criteria:\n\n* STEP 1 EXCLUSION ELIGIBILITY CRITERIA - CONCURRENT THERAPY\n* Patient must not have any active, known or suspected autoimmune disease and neuromuscular paraneoplastic syndromes including, but not limited to myasthenia gravis, Lambert-Eaton myasthenic syndrome, limbic encephalitis, myositis, Guillain-Barr\u00e9, systemic lupus erythematosus, and systemic sclerosis. Patients with type I diabetes mellitus requiring insulin, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are eligible\n* Patient must not have a history of active hepatitis B (chronic or acute) or hepatitis C infection. Patients with past or resolved hepatitis B infection (defined as having a negative hepatitis B surface antigen \\[HBsAg\\] test and a positive anti-HBc \\[antibody to hepatitis B core antigen\\] antibody test) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if polymerase chain reaction (PCR) is negative for hepatitis C virus ribonucleic acid (HCV RNA)\n* Patient must not have a known active tuberculosis infection\n* Patient must not have any severe infections within 4 weeks prior to registration including, but not limited to, hospitalization for complications of infection, bacteremia, or severe pneumonia\n* Patient must not have signs or symptoms of severe infection (sepsis) within 2 weeks prior registration\n* Patient must not have been treated with systemic immunostimulatory agents (including but not limited to interferon-a \\[IFN-a\\], interleukin \\[IL\\]-2) within 6 weeks or five half-lives of the drug (whichever is shorter) prior to registration; or treated with an investigational agent within 4 weeks prior to registration (or within five half-lives of the investigational agent, whichever is longer)\n* Patient must not have a history of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins\n* Patient must not have been treated with systemic immunosuppressive medications (equivalent to \\> 10 mg prednisone per day) or other immunosuppressive medications within 7 days prior to registration. Inhaled or topical steroids and adrenal replacement steroid doses equivalent to \\> 10 mg prednisone per day are permitted in the absence of active autoimmune disease\n* Patient must not have had a prior allogeneic bone marrow transplantation or prior solid organ transplantation\n* Patient must not have a history of idiopathic pulmonary fibrosis, pneumonitis (including drug induced), organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia, etc.), or evidence of active pneumonitis on screening chest computed tomography (CT) scan within 4 weeks prior to registration\n* Patient must not have had any prior systemic treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell costimulation or immune checkpoint pathways\n* Patient with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment and severity of cardiac symptoms. Symptoms should be stable over the past 3 months. Specifically, patient must not have coronary artery bypass grafting, myocardial infarction, acute coronary syndrome severe/unstable angina, stroke, transient ischemic attack, or heart failure hospitalization within 3 months prior to registration\n* Patient must not have an uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure, uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness/social situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events (AEs) or compromise the ability of the patient to give written informed consent\n* Patient must not have received a live, attenuated vaccine within 4 weeks prior to registration\n* Patient must not have had past radiation to the current intended treatment site\n* Patient must not donate blood or sperm while on study treatment\n* STEP 2 EXCLUSION ELIGIBILITY CRITERIA - CONSOLIDATION\n* Patient must not receive any non-protocol anti-cancer therapy after the end of Step 1 chemo/radiation or during Step 2 consolidation\n* Patients with suspected cases of \\>= grade 2 pneumonitis (non-infectious) are not eligible for Step 2 consolidative MEDI4736 (durvalumab) and will proceed onto follow-up instead\n* Patient must not have disease progression on the first post-treatment (Step 1 for concurrent chemo/radiation) chest CT scan, which must be obtained within 14 days after the last dose of radiation therapy. If so, the patient is not eligible for Step 2 consolidative MEDI4736 (durvalumab) and will proceed onto follow-up instead", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}, {"protocolSection": {"identificationModule": {"nctId": "NCT02339571", "briefTitle": "A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma", "officialTitle": "Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients With Unresectable Stage III or Stage IV Melanoma"}, "descriptionModule": {"briefSummary": "This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.", "detailedDescription": "PRIMARY OBJECTIVE:\n\nI. To compare the overall survival (OS) of nivolumab/ipilimumab/sargramostim (GM-CSF) versus nivolumab/ipilimumab.\n\nSECONDARY OBJECTIVES:\n\nI. To evaluate progression free survival (PFS) of patients treated with nivolumab/ipilimumab/GM-CSF versus nivolumab/ipilimumab.\n\nII. To assess for differences in tolerability, specifically the rate of grade III or higher adverse events, between nivolumab/ipilimumab/GM-CSF versus nivolumab/ipilimumab.\n\nIII. To evaluate immune-related response rate (based on immune-related response criteria) and response rate (based on Response Evaluation Criteria in Solid Tumors \\[RECIST\\] criteria) and to compare them.\n\nEXPLORATORY TOBACCO USE OBJECTIVES:\n\nI. To determine the effects of tobacco, operationalized as combustible tobacco (1a), other forms of tobacco (1b), and environmental tobacco exposure (ETS) (1c) on provider-reported cancer-treatment toxicity (adverse events \\[both clinical and hematologic\\] and dose modifications).\n\nII. To determine the effects of tobacco on patient-reported physical symptoms and psychological symptoms.\n\nIII. To examine quitting behaviors and behavioral counseling/support and cessation medication utilization.\n\nIV. To explore the effect of tobacco use and exposure on treatment duration, relative dose intensity, and therapeutic benefit.\n\nOUTLINE: Patients are randomized to 1 of 2 treatment arms.\n\nARM A: INDUCTION THERAPY: Patients receive nivolumab intravenously (IV) over 30 minutes on day 1, ipilimumab IV over 30 minutes on day 1, and sargramostim subcutaneously (SC) on days 1-14. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE THERAPY: Patients receive nivolumab and sargramostim as in induction therapy. Patients with partial response (PR), stable disease (SD), or complete response (CR) at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo magnetic resonance imaging (MRI), computed tomography (CT) scan, tumor biopsy and blood sample collection throughout the study.\n\nARM B: INDUCTION THERAPY: Patients receive nivolumab and ipilimumab as in Arm I. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity.\n\nMAINTENANCE THERAPY: Patients receive nivolumab as in induction therapy. Patients with PR, SD, or CR at 24 weeks may continue maintenance therapy for up to 2 years in the absence of disease progression or unacceptable toxicity. Patients undergo MRI, CT scan, tumor biopsy and blood sample collection throughout the study.\n\nAfter completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years."}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* All patients must be \\>= 18 years of age\n* Eastern Cooperative Oncology Group (ECOG) performance status: 0 or 1\n* Patients must have known BRAF mutational status of tumor; wild-type (WT) or mutated, prior to randomization\n* Patients must have unresectable stage III or stage IV melanoma according to American Joint Committee on Cancer (AJCC) version (v)7; patients must have histological or cytological confirmation of melanoma that is metastatic or unresectable and clearly progressive\n* Patients must have measurable disease per RECIST 1.1 criteria; all sites of disease must be evaluated within 4 weeks prior to randomization\n* Patients may have had prior systemic therapy in the adjuvant setting (e.g. interferon, BRAF, or MEK agents). Patients may have had prior anti-CTLA-4 in the adjuvant setting, if at least one year from last dose of treatment has passed prior to beginning treatment. Patients may have had any prior programmed cell death (PD)-1/PD-ligand (PD-L)1 agent in the adjuvant setting, if at least one year from last dose of treatment has passed prior to beginning treatment\n* Patients must have discontinued chemotherapy, immunotherapy or other investigational agents used in the adjuvant setting \\>= 4 weeks prior to randomization and recovered from adverse events due to those agents; mitomycin and nitrosoureas must have been discontinued at least 6 weeks prior to entering the study; patients must have discontinued radiation therapy \\>= 2 weeks prior to entering the study and recovered from any adverse events associated with treatment; prior surgery must be \\>= 4 weeks from randomization and patients must be fully recovered from post-surgical complications\n* White blood count \\>= 3,000/uL (obtained within 4 weeks prior to randomization)\n* Absolute neutrophil count (ANC) \\>= 1,500/uL (obtained within 4 weeks prior to randomization)\n* Platelet count \\>= 100,000/uL (obtained within 4 weeks prior to randomization)\n* Hemoglobin \\>= 9 g/dL (obtained within 4 weeks prior to randomization)\n* Serum creatinine =\\< 1.5 x upper limit of normal (ULN) or serum creatinine clearance (CrCl) \\>= 40 ml/min (obtained within 4 weeks prior to randomization)\n* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\\< 3 x ULN (=\\< 5 x ULN for patients with documented liver metastases) (obtained within 4 weeks prior to randomization)\n* Alkaline phosphatase =\\< 2 x ULN (=\\< 5 x ULN for patients with known liver involvement and =\\< 7 x ULN for patients with known bone involvement) (obtained within 4 weeks prior to randomization)\n* Total bilirubin =\\< 1.5 x ULN except subjects with normal direct bilirubin or those with known Gilbert's syndrome (obtained within 4 weeks prior to randomization)\n* Serum lactate dehydrogenase (LDH) =\\< 10 X ULN (obtained within 4 weeks prior to randomization)\n* Patients with autoimmune hypothyroid disease or type I diabetes on replacement treatment are eligible\n\nExclusion Criteria:\n\n* Patients must not be pregnant or breast-feeding due to use of cytotoxic immunotherapy and risk of teratogenic side effects; all patients of childbearing potential must have a blood test or urine study within 2 weeks prior to randomization to rule out pregnancy; a patient of childbearing potential is anyone, regardless of sexual orientation or whether they have undergone tubal ligation, who meets the following criteria: 1) has not undergone a hysterectomy or bilateral oophorectomy; or 2) has not been naturally postmenopausal for at least 24 consecutive months (i.e., has had menses at any time in the preceding 24 consecutive months)\n* Patients must not conceive or father children by using accepted and effective method(s) of contraception or by abstaining from sexual intercourse from the time of study registration and continuing (for patients of child bearing potential) for at least 5 months after the last dose of protocol treatment; patients of childbearing potential must also not donate eggs during this same time period\n* Patients may not have had any prior ipilimumab and/or anti-PD-1/PD-L1 agent in the metastatic setting\n* Patients must not receive any other investigational agents while on study or within four weeks prior to randomization\n* Patient must not have received any live vaccine within 30 days prior to randomization, while participating in the study, and for 4 weeks (28 days) after the last dose of protocol treatment; live vaccines include, but are not limited to, the following: measles, mumps, rubella, chicken pox, yellow fever, rabies, bacillus Calmette-Guerin (BCG), and typhoid (oral) vaccine' patients are permitted to receive inactivated vaccines and any non-live vaccines including those for the seasonal influenza and coronavirus disease 19 (COVID-19) (Note: intranasal influenza vaccines, such as Flu-Mist are live attenuated vaccines and are not allowed); if possible, it is recommended to separate study drug administration from vaccine administration by about a week (primarily, in order to minimize an overlap of adverse events)\n* Patients are ineligible if they have any currently active central nervous system (CNS) metastases; patients who have treated brain metastases (with either surgical resection or stereotactic radiosurgery) that have been stable on head magnetic resonance imaging (MRI) or contrast computed tomography (CT) scan for at least 4 weeks following treatment and within 4 weeks prior to randomization are eligible; patients must not have taken any steroids =\\< 14 days prior to randomization for the purpose of managing their brain metastases; patients with only whole brain irradiation for treatment of CNS metastases will be ineligible\n* Patients must not have other current malignancies, other than basal cell skin cancer, squamous cell skin cancer, in situ cervical cancer, ductal or lobular carcinoma in situ of the breast; patients with other malignancies are eligible if they have been continuously disease-free for \\> 3 years prior to the time of randomization\n* Patients must not have any serious or unstable pre-existing medical conditions (aside from malignancy exceptions specified above), including but not limited to, ongoing or active infection requiring parenteral antibiotics on day 1, history of bleeding diathesis or need for concurrent anticoagulation (international normalized ratio \\[INR\\] =\\< 1.5 and partial thromboplastin time \\[PTT\\] within 1.1 x ULN), or psychiatric illness/social situations that would limit compliance with study requirements, interfere with subject's safety, or obtaining informed consent\n* Patients with human immunodeficiency virus (HIV) infection are ineligible; due to the mechanism of action of ipilimumab and GM-CSF, activity and side effects in an immune compromised patient are unknown\n* Patients with evidence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection are not eligible; patients with cleared HBV and HCV (0 viral load) infection will be allowed\n* Patients must not have autoimmune disorders or conditions of immunosuppression that require current ongoing treatment with systemic corticosteroids (or other systemic immunosuppressants), including oral steroids (e.g., prednisone, dexamethasone) or continuous use of topical steroid creams or ointments or ophthalmologic steroids; a history of occasional (but not continuous) use of steroid inhalers is allowed; replacement doses of steroids for patients with adrenal insufficiency are allowed; patients who discontinue use of these classes of medication for at least 2 weeks prior to randomization are eligible if, in the judgment of the treating physician investigator, the patient is not likely to require resumption of treatment with these classes of drugs during the study\n* Exclusion from this study also includes patients with a history of symptomatic autoimmune disease (e.g., rheumatoid arthritis, systemic progressive sclerosis \\[scleroderma\\], systemic lupus erythematosus, Sjogren's syndrome, autoimmune vasculitis \\[e.g., Wegener's granulomatosis\\]); motor neuropathy considered of autoimmune origin (e.g., Guillain-Barre syndrome and myasthenia gravis); other CNS autoimmune disease (e.g., multiple sclerosis)\n* Patients must not have a history of inflammatory bowel disease or diverticulitis (history of diverticulosis is allowed)\n* Patients must not have other significant medical, surgical, or psychiatric conditions or require any medication or treatment that in the opinion of the investigator may interfere with compliance, make the administration of the study drugs hazardous or obscure the interpretation of adverse events (AEs), such as a condition associated with frequent diarrhea; patients must not have an active infection requiring current treatment with parenteral antibiotics", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}}}]